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Abstract  
 
Increasingly older adults are traveling to international destinations with malaria as a present risk. 
Surveillance systems indicate that older adults are more likely to suffer severe complications 
from malaria.  The role of health care providers in selecting an appropriate medication for 
chemoprophylaxis or treatment of malaria in adults becomes more difficult as older adults 
undergo physiologic changes that alter the pharmacokinetic and pharmacodynamic nature of 
medications potentially causing increased drug interactions, adverse events, and altered drug 
action.  A comprehensive literature search from 1970 to present, with a focus on the last 10 
years, was conducted on drug interactions, pharmacokinetic and pharmacodynamic effects on 
antimalarials in adults.  It was determined that due to pharmacodynamic and pharmacokinetic 
changes in older adults, especially renal and cardiovascular,  special attention should be given to 
this population of travelers in order to minimize the likelihood of adverse events or altered drug 
efficacy. Antimalarial-disease interactions in older adults can occur more often due to QT 
prolongation, exacerbation of hypoglycemia, decreased renal elimination, and decreased hepatic 
metabolism. Older antimalarials have well documented drug-drug interactions.  Tafenoquine, a 
new antimalarial, requires G6PD screening like primaquine and monitoring of new potential 
drug interaction with MATE1 and OCT2 substrates. While drug-drug interactions in older 
travelers may occur more often as a result of poly-pharmacy, data does not indicate adverse 
reactions or decreased drug efficacy is greater compared with younger adults.  Overall, with the 
exception of recently approved tafenoquine, much is known about antimalarial drug and disease 
interactions, but new drugs are always being approved, requiring travel health providers to 
understand the pharmacokinetics and pharmacodynamics of antimalarial drugs to predict the 
impact on safety and efficacy in travelers. This guide provides travel health providers with 
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valuable insights on potential outcomes associated with drug interactions in adults and 
recommended monitoring or drug regimen modification.  
 
Keywords: older traveler, atovaquone-proguanil, doxycycline, primaquine, tafenoquine, 
mefloquine, chloroquine, artemisinins, artesunate, artemether, hepatic enzyme induction, QT 
prolongation 
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Introduction 
Older adults make up an increasingly larger proportion of the traveling population.
1
 
Those over 60 years of age represent about 8% of ill returned travelers, but of those, more have 
severe disease compared to younger travelers.
2
  In 2016, the U.S. Centers for Disease Control 
and Prevention (CDC) received 2,078 reports of imported malaria, the most since 1972.
3
 While 
the percentage of adults 65 years and older only accounted for 6.3% of those with malaria in this 
report, 19.2% of them developed severe malaria, which included cerebral and kidney damage as 
well as acute respiratory distress syndrome.  Studies in Asia and Europe indicate the incidence of 
hyperparasitemia and renal insufficiency increase with age, and the risk of death due to 
falciparum malaria increases by 85% per decade of life.
4, 5
  It has been suggested that the 
increased susceptibility to severe malaria might be due to a waning immune system or 
atherosclerosis, which is more common in older adults.
6
 Also, older adults undergo physiologic 
changes that compromise the pharmacokinetic and pharmacodynamic nature of the medications 
they take, leading to increased drug-drug interactions, adverse events, and altered drug action.
7
  
An analysis of TravEpiNet, a large CDC funded pre-travel project, revealed that of potential 
drug-drug interactions, 61% occurred in those over 50 years of age and 41% had at least three 
comorbid conditions.
8
  Since 1988, the number of medications taken by adults 65 years and older 
have doubled, and those taking 5 or more medications have tripled.
9
  A recent systematic review 
underscored the need to not only consider the implications of pharmacologic changes associated 
with aging, but also that older adults are more likely to forego insect protection and may be less 
likely to adhere to antimalarial regimens.
10
  This review aims to address the drug-drug, drug-
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disease, physiologic and pharmacokinetic changes in older adults that are critical to protecting 
this vulnerable population against malaria and its severe complications.   
 
Methods 
A comprehensive literature search from 1970 – present, with a focus on the last 10 years, 
was conducted to identify relevant studies and background information on the use of 
antimalarials in older adult travelers. Database searches were conducted in PubMed, Cochrane 
Database of Systematic Reviews, WHO Global Index Medicus, Web of Science, and CINAHL. 
Searches were conducted using the keywords and mesh terms: aged, antimalarials, artemisinin, 
atovaquone-proguanil, chemoprophylaxis, chloroquine, doxycycline, drug-drug interactions, 
malaria, mefloquine, primaquine, tafenoquine, and travel. International trade names for the 
antimalarials were searched on drugs.com and through the monographs Index Nominum and 
Martindale: the Complete Drug Reference. Search results were also limited to English-language 
studies and humans. References of identified articles were reviewed to identify any additional 
studies not found in the initial search. The search was conducted by four independent authors. 
After thorough discussion among the authors, articles were selected for inclusion into this 
manuscript based on their relevance to the topic as well as detailed and complete results. 
Results 
Pharmacokinetic and Pharmacodynamic Changes 
Due to physiological changes associated with aging, the pharmaceutical care of older 
adults differs from younger adults. Changes in important organ systems like the renal and 
cardiovascular affect the pharmacokinetics (i.e., drug absorption, distribution, metabolism, and 
excretion) and pharmacodynamics (i.e., effect of drug at the target site) of medications.
11, 12
 For 
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example, with increased age there is a relative decrease in total body water, lean muscle mass, 
and increase in percentage of body fat.
11-13
 These changes will alter the usual volume of 
distribution, primarily for lipophilic drugs, resulting in a longer elimination half-life.
12
 Hepatic 
metabolism of drugs in older adults can be reduced by up to 30% while renal excretion can be 
decreased by 50%.
14
 Drug clearance by the liver depends on perfusion and extraction ratio.
12
 
Since extraction ratio is dependent on the metabolizing capacity of the liver, a decrease in 
hepatic drug metabolism may also reduce hepatic drug clearance.
12
 
Pharmacodynamic changes in older adults usually results in increased or decreased drug 
sensitivity, depending upon the class of medication.
12
 Reasons for pharmacodynamic changes in 
older adults are less well understood but are most pronounced for cardiovascular and central 
nervous system effects of various drugs.
11, 15
 
Changes in older adults are important considerations when selecting an antimalarial 
medication for prophylaxis or treatment. Some common adverse events with antimalarial agents 
that warrant more consideration in older adults are a risk for QT prolongation and hypoglycemia. 
Many antimalarial drugs can cause QT prolongation and in older adults there is increased risk of 
this due to pre-existing cardiovascular disease, use of concurrent QT-prolonging drugs and age-
related increases in QT interval.
11, 15, 16
 Some antimalarial drugs can cause insulin production 
resulting in increased risk of hypoglycemia especially in older adults on concurrent anti-diabetic 
medications.
17, 18
 There is also strong concern for drug-drug and drug-disease interactions in 
older adults due to increased medication use and comorbidities with age.
11
  
 
Atovaquone-proguanil  
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 Atovaquone-proguanil is indicated for prophylaxis and treatment of uncomplicated 
malaria in adults and children weighing 5 kg or greater.  
 
Pharmacologic/Pharmacokinetic Effects 
Atovaquone and proguanil are both active against all stages of the malaria parasite life 
cycle.
19, 20
 Atovaquone is a hydroxynaphthoquinone and is a ubiquinone analogue that disrupts 
the cytochrome electron transport system and hinders the transport of several parasite enzymes 
which lowers the mitochondrial membrane potential.
20, 21
 Proguanil must be converted into the 
active metabolite, cycloguanil, which inhibits dihydrofolate reductase in the Plasmodium species 
leading to the inhibition of deoxythymidylate synthesis.
22
   
Atovaquone is a lipophilic compound, and thus, it is poorly absorbed from the GI tract. In 
older adults, lipophilic drugs may have a larger volume of distribution with a longer half-life 
resulting in greater systemic exposure and an increased risk for adverse effects.
14
 Proguanil is 
readily absorbed from the GI tract. To increase absorption, atovaquone-proguanil should be 
taken with food, preferably a fatty meal, at the same time every day, which increases the 
bioavailability to 21-23%.
23, 24
 Atovaquone has a half-life of about 2-3 days in adults due to 
enterohepatic recycling.
23
 While it is highly protein bound (>99%), atovaquone does not seem to 
displace other highly protein-bound drugs in vitro.
23
 Proguanil is 75% protein bound and it has a 
half-life of 12-21 hours.
23
 According to the manufacturer, single-dose pharmacokinetics of 
atovaquone, proguanil, and cycloguanil were studied in 13 elderly subjects (65-79 years of age) 
and compared to 13 younger subjects (30-45 years of age).
23
 Systemic exposure, or area under 
the curve, of cycloguanil was higher in the older adult population (point estimate 2.36, 95% CI 
1.70 to 3.28). The Tmax and elimination half-life were longer in the older adult population when 
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compared to the younger population (8 hours vs 4 hours and 14.9 hours vs 8.3 hours, 
respectively).
23, 25
 When using atovaquone-proguanil in older adults the possibility of higher 
systemic exposure to the medication should be considered as the likelihood for adverse effects 
may be greater.        
Undetectable amounts (<0.6%) of atovaquone pass through the kidney.
26
 About 40-60% 
of proguanil is excreted renally.
23, 25
 In patients with severe renal impairment there is a risk for 
pancytopenia which can result from proguanil accumulation.
27 
Thus, for patients with CrCl <30 
mL/min prophylaxis with atovaquone-proguanil is contraindicated and treatment of malaria with 
atovaquone-proguanil should only be used if the benefits outweigh the risks. These are important 
considerations in older adults as they are more likely to have renal impairment than younger 
individuals.
12
  
Atovaquone is almost primarily excreted via the liver.
26
 It has been postulated that some 
of atovaquone also undergoes enterohepatic recirculation.
26
 Proguanil undergoes hepatic 
metabolism via CYP2C19 and CYP3A4 at which time it is converted into cycloguanil.
23, 28
 There 
are currently no dosage adjustment recommendations for atovaquone-proguanil in patients with 
mild to moderate hepatic impairment. Studies have not been conducted in patients with severe 
hepatic impairment taking atovaquone-proguanil.
23
 
 
Pharmacodynamic Effects  
Although mostly well-tolerated, atovaquone-proguanil may cause gastrointestinal (GI) 
disturbances such as abdominal pain, nausea, vomiting, and diarrhea.
23
 Rarely, allergic reactions, 
blood disorders, photosensitivity, rash, increased liver enzymes, hepatitis, and hepatic failure 
may occur.
23
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Drug-drug Interactions 
Rifampin and rifabutin can decrease plasma concentrations of atovaquone by up to 
52%.
23, 29
 (Table 1) The mechanism of this interaction is not known, but it has been suggested 
that the ability of rifamycin to induce hepatic enzymes and drug transporters may be 
responsible.
26
 Certain HIV medications such as efavirenz, lopinavir/ritonavir, and 
atazanavir/ritonavir have also been shown to lead to lower plasma concentrations of atovaquone 
and proguanil.
30, 31
 (Table 1) Although not demonstrated, studies have suggested that this may be 
due to atovaquone plasma protein displacement of these drugs.
26, 30
  Similarly, the plasma 
concentration of atovaquone may be reduced by 40% when taken with tetracycline and the 
bioavailability of atovaquone may be lower if taken with metoclopramide.
23
  (Table 1) If these 
drug interactions cannot be avoided, dosage adjustments and closer monitoring of patients for the 
development of malaria is warranted. Atovaquone may increase the plasma concentrations of 
zidovudine, by inhibiting its metabolism through glucuronidation, and etravirine and saquinavir, 
by interfering with CYP450 mediated metabolism, possibly on the 2C isoenzymes.
32, 33
 
Atovaquone-proguanil may potentiate the anticoagulant effect of warfarin by increasing the free 
warfarin concentrations through plasma protein displacement.
26, 34-36
 (Table 1) Closer monitoring 
of the warfarin dose is necessary to avoid excessive bleeding. Proguanil, at twice the dose used 
in the adult formulation of atovaquone-proguanil, may decrease the efficacy of the oral typhoid 
vaccine due to in vitro antibacterial activity that decreases replication of the vaccine strain in 
vivo, which in turn, diminishes vaccine efficacy.
37
  However, subsequent work in children using 
atovaquone-proguanil showed no decrease in the immunogenicity of the oral typhoid vaccine and 
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thus the Centers for Disease Control and Prevention state it may be given together or at any 
interval.
38, 39
   
Drug-disease Interactions and Considerations in Older Adults 
For patients with HIV and those patients taking rifampin, rifabutin, or warfarin an 
alternative agent should be considered for malaria prophylaxis or treatment. An increase in age 
leads to an increase in potential for comorbidities and the need for anticoagulation.
40
 Thus, older 
adults are more likely to be on warfarin therapy and this should be a consideration with 
atovaquone-proguanil. INR should be closely monitored at baseline and throughout therapy. 
Kidney function should also be evaluated prior to start of therapy.   
 
Doxycycline  
Doxycycline is indicated for chemoprophylaxis and treatment of severe or uncomplicated 
malaria. 
 
Pharmacologic/Pharmacokinetic Effects 
Doxycycline is a broad-spectrum antibiotic. It is synthetically derived from oxytetracycline 
which makes it related to tetracycline.
19
 The dosage for chemoprophylaxis of malaria is 100 mg 
once daily, whereas for many other indications, it is given twice daily.  Thus, the magnitude of 
pharmacodynamic effects for non-malaria dose studies should be interpreted with caution. 
Doxcycline has a longer half-life than tetracycline and a better absorption profile.
19
 As an anti-
malarial medication, it interrupts the apicoplast function in plasmodium thereby inhibiting 
protein synthesis.
41, 42
 After oral administration, doxycycline is quickly and almost entirely 
absorbed.
43
 Divalent cations,  such as calcium in dairy products, and trivalent cations decrease 
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doxycycline absorption, but otherwise, doxycycline is not affected by food.
44, 45
 It does undergo 
enterohepatic recirculation which may slow clearance of the medication and it is primarily 
excreted by chelation in the GI tract.
43
 One study found that the apparent volume of distribution 
of doxycycline was higher in older adults 65-90 years of age (mean 76.3 ±6 years) compared to 
younger individuals.
46
  
 The clearance of doxycycline is similar in individuals with normal renal function and in 
those with renal impairment.
47
  No dosage modifications are needed for hepatic insufficiency.  
 
Pharmacodynamic 
Gastrointestinal 
Doxycycline may cause gastric irritation. Doxycycline hyclate has been shown to cause 
more gastrointestinal side effects than doxycycline monohydrate and the incidence of esophageal 
ulcers is higher with doxycycline hyclate capsules than with tablets.
43, 48
 Because of this, GI 
disturbances such as nausea and abdominal pain commonly occur as well as vomiting and 
diarrhea, which are less common.
43
 To lessen the likelihood of this adverse effect and to avoid 
esophagitis, doxycycline should be taken with food, a full glass of water and in an upright 
position.
49
 Dysphagia, esophageal ulceration, dry mouth, glossitis, enterocolitis, and stomatitis 
have also been reported.
9
 While once thought to increase the rate of Clostridium difficile 
infection, newer evidence suggests it may decrease the rate.
50
 
Dermatologic 
Photosensitivity is a common adverse effect of doxycycline. Patients should avoid 
excessive sun exposure while on this medication and ensure the use of sunscreen when going 
outdoors. Other adverse effects include inflammatory lesions in the ano-genital region, skin 
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reactions, exfoliative dermatitis, and hypersensitivity reactions.
19
 Case reports mention skin-
hyperpigmentation, post-inflammatory elastolysis, and tooth discoloration with long-term 
doxycycline use.
43
 
Other 
Although not reported in patients taking doxycycline for malaria prevention, doxycycline 
has rarely been associated with benign intracranial hypertension.
43
 Hematologic abnormalities 
have been reported in rare cases.
51
           
 
Drug-drug Interactions 
Dairy products, such as milk, decrease the absorption of doxycycline due to their calcium 
content. Antacids, bismuth subsalicylate, proton pump inhibitors, and oral iron products also 
decrease the absorption of doxycycline.
52-54
 (Table 1) In addition, older adults are at higher risk 
for adverse effects with PPIs.
55, 56
 In a Gallup Survey, 22% of responders who were greater than 
50 years old stated they used antacids and other anti-dyspepsia agents two or more times per 
week.
57
 In this same poll, only 9% of the responders younger than 50 admitted to doing the 
same.
57
 Since older adults are more likely to be taking these agents, and many are over the 
counter, health care providers should discontinue or seek alternatives to these types of 
medications prior to prescribing doxycycline.  
 Hepatic enzyme inducers such as certain antiepileptic drugs, rifampicin, and chronic 
alcohol use may increase the metabolism of doxycycline.
58-62
 (Table 1) Another major 
interaction that has been described in literature is the competitive plasma protein displacement of 
methotrexate by doxycycline leading methotrexate toxicity.
36
 (Table 1) Over anticoagulation can 
occur when warfarin and doxycycline are given together through pharmacodynamic inhibition of 
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vitamin K dependent coagulation factors, and pharmacokinetic, protein binding displacement, 
mechanisms.
63
 (Table 1)   
Drug-disease Interactions and Considerations in Older Adults 
Anticoagulation 
With increasing age, there is an increased likelihood for comorbidities, such as atrial 
fibrillation, and the need for anticoagulation and older adults are also at an increased risk for 
hemorrhage from anticoagulation therapy.
40, 64 
Doxycycline should be avoided or the INR needs 
to be monitored closely with the concomitant use of warfarin, especially in older adults. 
Fungal infections 
Due to the suppression of vaginal bacterial flora, doxycycline has been implicated in the 
development of candidal vulvovaginitis.
43
 Individuals predisposed to candidal vulvovaginitis, 
such as those with diabetes mellitus, or prior medical history of recurring vulvovaginitis, may 
benefit from carrying a course of antifungal treatment on their trip.
43, 65
 Elevated blood sugars 
may predispose patients to candida infections. Older adults are more likely to have diabetes and 
thus, they should be counseled regarding the increased risk for candida infections especially if 
they will take doxycycline for a prolonged period of time.
66
 
Photosensitivity 
As older adults are more likely to have comorbid conditions such as diabetes and hypertension, 
they may already be taking certain medications such as thiazide diuretics and sulfonylureas 
which may cause photosensitivity.
40, 51, 66
 As doxycycline may also cause photosensitivity
51
, 
patients should be counseled to wear extra sunscreen while traveling.  
 
Mefloquine   
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 Mefloquine is indicated for the prophylaxis of malaria and the treatment of mild-to-
moderate, uncomplicated, chloroquine-resistant P. vivax and uncomplicated P. falciparum 
malaria in combination with Artesunate. 
 
Pharmacologic//Pharmacokinetic Effects  
Mefloquine is a quinoline-methanol compound structurally similar to quinine. Mefloquine acts as 
a blood schizonticide but its exact mechanism of action is not known. It is a 4-aminoquinoline 
with a fairly large volume of distribution, is highly protein bound and is primarily distributed in 
the tissue.
42, 67
 With increased age, protein binding can potentially be affected. Healthy older 
adults will have normal concentrations of important proteins like albumin and alpha-1-acid 
glycoprotein which may be decreased by malnutrition and frailty.
11
 While mefloquine is a highly 
protein bound drug, no changes in dosing based on weight or composition are currently 
recommended.
68
  
Mefloquine is primarily metabolized via CYP enzymes in the liver.
69
 Although the 
natural decrease in liver function that occurs with aging will not usually affect mefloquine use, 
caution should be taken in patients with liver disease.
70
 There are currently no dose adjustment 
recommendations for hepatic impairment; however, the half-life is increased leading to 
prolonged plasma levels.
70
 With increased drug exposure there is increased risk for adverse 
effects including headache, gastrointestinal disturbances, nervousness, fatigue, disorders of sleep, 
mood, memory and concentration, and occasionally psychosis.
71
 
As only a small amount of mefloquine is renally eliminated, no major renal 
considerations exist for the use of mefloquine. 
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Pharmacodynamic Effects 
Mefloquine may cause bradyarrhythmia, gastrointestinal issues, dizziness, headache, 
insomnia, hallucinations and anxiety.
72
 Mefloquine has also been associated with other serious 
side effects which include QT interval prolongation, seizures, suicidal ideations, and 
pneumonitis.
72
  
 
Drug-drug Interactions 
As most drugs are hepatically metabolized, mefloquine does interact with other drugs that 
rely on similar metabolism routes in the body. Both ketoconazole and ampicillin lead to higher 
concentrations of mefloquine by decreasing its metabolism in the liver.
67, 73
  (Table 1) 
Conversely, CYP enzyme inducers such as rifampin can lead to decreased mefloquine 
concentrations.
74
 (Table 1) Ritonavir and mefloquine seem to interfere which each other’s 
metabolism to varying extents but the clinical impact is unclear.
75
 
Mefloquine can affect cardiac conduction, specifically slowing the heart rate and 
increasing risk for QT prolongation.
76, 77
 Given this risk the WHO recommends caution when 
using mefloquine with drugs that also affect cardiac conduction such as calcium channel 
blockers, digoxin, amiodarone, quinolones, β-blockers, and other quinines.
42
  (Table 1)  
 
Drug-disease interactions and Considerations in Older Adults  
Neuropsychiatric 
Mefloquine use is contraindicated in patients with epilepsy.
78
 Additionally, one of the 
major concerns with mefloquine is the rare risk for neuropsychiatric adverse events including 
anxiety, depression, mood changes, panic attacks, forgetfulness, confusion, hallucinations, 
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aggression, psychotic or paranoid reactions.
79
 The CDC recommends avoiding use of mefloquine 
in patients with pre-existing psychiatric disease or a strong family history of psychiatric 
disease.
80
 This caution should especially be exercised in older adults as data shows 52% of 
patients with first onset of a mood disorder at age 60 or older.
81
 There is no evidence to suggest 
older adults are at higher risk of neuropsychiatric adverse events, however they should 
appropriately be screened for mood disorders prior to use of mefloquine especially when used for 
long term prophylaxis.   
  Cardiac 
As the incidence of cardiovascular disease such as arrhythmias and the use of 
antiarrhythmic drugs increases with age, older adults may be at a greater risk for cardiotoxicity 
especially if taking mefloquine with a medication that affects cardiac conduction.
82
 Caution 
should be exercised if prescribing mefloquine to ensure that drug-drug interactions, especially 
those that affect cardiac conduction, are not present.  
 
Primaquine 
 Primaquine is indicated for the prophylaxis of malaria and treatment, including radical 
cure of Plasmodium vivax and P. ovale infections and presumptive anti-relapse therapy.    
 
Pharmacologic/Pharmacokinetic Effects 
Primaquine phosphate is an 8-aminoquinoline active against malaria parasites in the 
erythrocytic, hepatic, and gamete phase of the plasmodium’s life cycle.
83
  
Primaquine is broken down by monoamine oxidase into a predominant inactive 
metabolite, carboxyprimaquine, which lacks efficacy and toxicity, as well as by CYP2C19, 
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CYP2D6, and CYP3A4 enzymes into metabolites which are responsible for the antimalarial and 
hemolytic toxicity of primaquine.
84-86
 The CYP2D6 enzyme may be essential for antimalarial 
efficacy of primaquine, and thus, the reduction in its activity may result in treatment failure.
86
 
Once it is distributed in the body, primaquine is found in erythrocytes in high concentrations. 
Primaquine is readily absorbed from the GI tract with 96% bioavailability.
87
 Primaquine and 
carboxyprimaquine are primarily excreted through the biliary tract; however, some of 
primaquine is also excreted unchanged in the urine.
88
 The elimination half-life is 4 to 7 hours and 
no dosage adjustment is needed for renal insufficiency.
89, 90
 Although clinical studies have not 
identified differences in response to treatment with primaquine in older adults versus younger 
patients, the manufacturer recommends starting with low doses of this drug due to potential 
physiologic changes in older adults.
83
  
 
Pharmacodynamic Effects 
Primaquine is usually well-tolerated. It may cause some GI discomfort which may be 
dose-related.
83
 If this occurs, patients can take primaquine with food. Rarely, hypertension, QT 
prolongation and cardiac arrhythmias occur.
83
   
 
Drug-drug interactions 
 There are no clinically significant drug interactions resulting in toxicity with currently 
marked drugs and primaquine.  Quinine use may decrease the plasma concentration of 
carboxyprimaquine, an inactive metabolite, by interfering with the production and elimination of 
carboxyprimaquine.
91
 Dihydroartemisin-piperaquine and artesunate-pyronaridine may increase 
the levels of primaquine and carboxyprimaquine by displacing bound primaquine and 
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carboxyprimaquine from the tissues.
85, 91
 Chloroquine has also been shown to increase 
primaquine geometric mean plasma concentration by 63%, which does not result in toxicity but 
may have a synergistic effect.
92
 While no recent studies confirm these interactions, the 
manufacturer of primaquine reports interactions with quinacrine and myeloid suppressive drugs. 
(Table 1)
83
   
 
Drug-disease Interactions and Considerations in Older Adults 
G6PD deficiency 
The most important adverse effect with primaquine is hemolysis which results when 
patients are G6PD deficient. There are different variants of G6PD deficiency and these are 
associated with different risks for hemolysis. In G6PD deficient people, hemolysis usually occurs 
2 to 3 days after primaquine initiation. Both qualitative and quantitative point-of-care G6PD 
testing is now available. The CDC states that quantitative G6PD deficiency testing must be done 
prior to primaquine use.
93
 The severity of hemolysis depends on the dose, length of therapy, and 
degree of G6PD deficiency. As primaquine is rapidly eliminated from the body, hemolysis stops 
shortly after drug discontinuation. If primaquine must be used, it can be dose adjusted depending 
upon the degree of G6PD deficiency.
94
 Hemolytic anemia, leukopenia, methemoglobinemia, and 
granulocytopenia may also occur independently of G6PD deficiency.
89
         
Rheumatoid arthritis and SLE 
Primaquine use is contraindicated in acutely ill patients with granulocytopenia such as 
patients with a severe subset of rheumatoid arthritis (RA) and SLE.
95
 This is an important 
consideration especially in older adults who are more likely to suffer from RA than younger 
individuals.
95
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Other 
Loss of efficacy has been observed in patients with poor and intermediate P450 CYP2D6 
activity phenotypes since isoenzyme 2D6 may be primarily responsible for metabolizing 
primaquine into active metabolites against hypnozoites in the liver.
96
     
 
 
Drug Name: Tafenoquine 
 Arakoda® (US trade name) and Kodatef® (Australian trade name) are indicated for the 
prophylaxis of malaria. Krintafel® (US trade name) and Kozenis® (Australian trade name) are 
indicated for radical cure of P.vivax malaria.   
 
Pharmacologic/Pharmacokinetic Effects 
 Similar to primaquine, tafenoquine is an 8-aminoquinoline.
97, 98
 It is active against all 
stages of the parasite, including dormant liver stages of P.vivax and erythrocytic phase, having a 
similar efficacy to mefloquine for prophylaxis.
99
  
 Unlike primaquine, tafenoquine is eliminated from the body at a much slower rate. The 
terminal half-life of tafenoquine is 12-15 days, and co-administration with a high-fat meal 
increases systemic exposure by 41%.
94, 100
 The longer half-life allows for weekly dosing where 
primaquine must be dosed daily. Age does not appear to impact the pharmacokinetics of 
tafenoquine.
101, 102
  
Tafenoquine has not been studied in patients with renal and hepatic disease, however 
renal and hepatic function should be monitored in patients with pre-existing disease.
94
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Pharmacodynamic Effects 
 Gastrointestinal 
The adverse effect profile of tafenoquine is like that of primaquine. GI disturbances such 
as nausea, diarrhea, vomiting and motion sickness have occurred. If taken with food, the GI 
adverse effects of tafenoquine may be minimized.  
Hematologic 
Moderate methemoglobinemia has been reported but is likely due to higher doses (>200 
mg) daily or weekly.
94
 When used as a single dose, this adverse effect is very rare.
94
  
Ophthalmic 
Corneal deposits or epithelial keratopathy with prolonged use can occur with tafenoquine. 
This was observed in 25% of individuals taking the drug for 6 months and it resolved within 12-
48 weeks upon discontinuation of the drug.
94, 103
  
Other 
Depression, photophobia, increased serum creatinine and serum alanine 
aminotransferase, insomnia, and decreased hemoglobin have also been reported but with lesser 
frequency.
104
  
 
Drug-drug Interactions 
Tafenoquine may increase the levels of multidrug and toxin extrusion (MATE1) 
substrates and organic cation transporter  (OCT2) substrates, which are renal transporters 
important in renal elimination of drugs.
105
 If one or both renal transporters are inhibited as is the 
case with tafenoquine, this can lead to toxicity of the substrates. Therefore, a combination of 
tafenoquine with MATE1 or OCT2 substrates should be avoided. However, if the drugs must be 
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given together a dose reduction of MATE1 or OCT2 substrates should be considered to avoid 
toxicity. Cisplatin, oxaliplatin, and metformin are a few examples of OCT2 and MATE2 
substrates that have increased plasma levels when given with tafenoquine.
105-107
 (Table 1) As the 
likelihood for diabetes increases with age
108
, this may be an important consideration to take note 
of since many patients with diabetes are often prescribed metformin for management of 
diabetes.
109
 Tafenoquine has little effect on cytochrome P450 metabolized drugs like primaquine, 
nor does it affect the pharmacokinetics of chloroquine when co-administered.
110
 Tafenoquine has 
not been adequately studied in older adults.  
 
Drug-disease interactions and Considerations in Older Adults 
G6PD deficiency 
As with primaquine, G6PD deficiency must be screened for prior to administration of 
tafenoquine due to increased risk for hemolytic anemia.
104
 Females with a quantitative activity of 
G6PD ≥30% to <70% are considered to be in the intermediate category, but because tafenoquine 
has dose dependent hemolysis, males and females should have a quantitative test done to ensure 
the activity is greater than 70% before it can be used for prophylaxis or treatment.
94
  
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common genetic 
disorder in humans.
94
 Since the G6PD gene lies on the X chromosome, males with a mutation on 
the X chromosome and females with a mutation on both X chromosomes will have full 
phenotypic expression of the deficiency.
94
 Females with a mixture of G6PD normal and G6PD 
deficient red cells will have varying levels of G6PD deficiency.
94
 Qualitative testing for G6PD 
deficiency is sufficient for males as they are either G6PD deficient or normal.
94
 However, for 
females, a quantitative test must be done because of the possibility of having an intermediate 
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level of G6PD deficiency.
94
 The threshold for normal G6PD qualitative test is ≥30%.
94 
Thus a 
female heterozygous patient testing ―normal‖ may still have up to 70% of their red blood cells 
G6PD deficient.
111
 As most patients with G6PD deficiency remain asymptomatic, it is possible 
that an older adult does not know their G6PD status.
112
   
Hematologic 
Methemoglobin elevations have been reported with tafenoquine use and this should be 
considered prior to prescribing the medication, especially if used at higher doses.
110
  
Neurologic 
Tafenoquine should also be used with caution in patients with psychiatric disorders. With 
higher doses of tafenoquine, serious psychiatric adverse events have been reported in patients 
with a past medical history of psychiatric disorders.
113
  Anxiety, abnormal dreams, mood 
changes, and trouble sleeping have been observed.
104
 These effects may have a delayed onset due 
to longer half-life and longer time to Cmax of the drug.
101
 This is an especially important 
consideration in older adults as data shows that the first onset of a mood disorder occurs at age 
60 or older in 52% of patients.
81
 Patients with a history of psychotic disorders or current 
psychotic symptoms, especially in deployed military personnel, should not use this drug.
97, 114
   
  
Artemisinins Artesunate and Artemether 
 Artesunate is administered intravenously for the treatment of severe malaria and 
Artemether with Lumefantrine (AL), with the trade name of Coartem® in US and Africa and 
Riamet® in Europe, is used orally for treatment and standby emergency treatment of 
uncomplicated malaria. 
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Pharmacologic/Pharmacokinetic Effects 
Both artemether and artesunate have similar pharmacodynamic properties as other 
artemisinin derivatives.
115
 The mechanism of action of the artemisinins is hypothesized to 
involve an iron-mediated cleavage of the endoperoxide bridge, which produces oxygen free 
radicals, which then react with nearby molecules, interfering with parasite function.
116
 Both 
artesunate and artemether are prodrugs that are rapidly hydrolyzed by plasma esterases to an 
active metabolite, dihydroartemisinin (DHA), which then undergoes hepatic metabolism via 
CYP2B6, CYP2C19, and CYP3A4 to inactive metabolites.
117
 Bodyweight has been linked to 
differences in dosage necessary of artesunate, with children requiring higher dosages due to a 
larger volume of distribution.
42
 No enhanced measures are recommended for older adults with 
lower body weight.  The exact mechanism of action of lumefantrine is unknown but it is thought 
to prevent the formation of β-hematin by complexing with hemin, inhibiting nucleic acid and 
protein synthesis, and eliminating residual parasites. While artemether clears most of the 
parasitemia, lumefantrine concentrations that remain at the end of the 3- to 5-day course, due to 
its long half-life of 3-6 days, are responsible for eliminating residual parasites.
118
 There is no 
renal or hepatic dose modification necessary with the artemisinins, but they should be used 
cautiously in severe impairment.  A high-fat meal, as little as 1.2 g, can significantly increase the 
AUC of lumefantrine, 5 fold, and artemether.
119, 120
  
 
Pharmacodynamic Effects 
Hypersensitivity reactions, some gastrointestinal disturbances, dizziness, 
reticulocytopenia, and an increase in liver enzymes have been reported.
42
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Drug-drug interactions 
Similar to other antimalarials previously discussed, the artemesins and DHA, the active 
metabolite, interact with potent CYP 3A4 inducers and inhibitors as noted. With the short half-
life of intravenous artesunate, it is unlikely to incur clinically significant drug-drug 
interactions.
121
  The drug-drug interactions with the best documentation are between AL and 
ketoconazole and rifampin.
122
 Ketoconazole can increase levels of AL and DHA by CYP 3A4 
inhibition 1.6 to 2.3 fold, leading to QT interval prolongation.
120
 Rifampicin, on the other hand, 
is a CYP 3A4 enzyme inducer, thus, theoretically, leading to a decrease in AL plasma levels and 
a potential decrease in antimalarial efficacy.
123
  The pharmacokinetic decrease of DHA with 
ritonavir and similar drugs is thought to be due to the induction of uridine diphosphate-
glucuronosyltransferases (UGTs), the main route of elimination of DHA, by ritonavir. 
124
 
Decreased exposure of DHA observed with ritonavir may negatively impact efficacy of 
antimalarial therapy. Lumefantrine is also mainly metabolized by CYP3A4. Administration with 
potent inducers of CYP3A4 may result in lower lumefantrine, artemether and DHA exposure and 
potential failure of treatment. In clinical studies, artemether and DHA exposure were 
substantially lower with concomitant use of nevirapine (NVP) and efavirenz (EFV).
125, 126
  
Efavirenz, is a potent CYP 3A4 inducer and has shown to decrease the AUC of DHA by 50%, 
potentially leading to AL treatment failure.
127
 Results with lumefantrine and NVP have been 
mixed as NVP is a less potent inducer of CYP3A4 than EFV.  In the South African and 
Tanzanian studies, they found lumefantrine exposure increased at the end of a simulated 7-day 
course, but a Ugandan study found a decrease in lumefantrine AUC.
125, 126, 128
 Speculation as to 
the difference in effect on lumefantrine in the South African study is they provided a high fat 
meal to participants and extended the regimen, which may be necessary to overcome this 
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interaction with NVP.
128
 Conversely, when lumefantrine and the HIV drug lopinavir/ritonavir 
were co-administered to HIV positive study participants, lumefantrine plasma concentrations 
were 10 times greater with no documented increase in adverse effects.
129
 Whether this interaction 
leads to better efficacy needs further study. A summary of drug-drug interactions and 
artemisinins is listed in Table 1.  
 
Drug-disease interactions and Considerations in Older Adults 
 Cardiac 
While lumefantrine is structurally similar to halofantrine, which is known to cause 
significant cardiotoxicity, pharmacologic modifications to the drug have borne out no increase in 
QT prolongation.
130, 131
  The manufacturer, however, recommends against use in patients with 
congenital QT prolongation and patients receiving other drugs known to affect the QT 
interval.
120
 As mentioned previously, older adults may be at a greater risk for cardiotoxicity as 
the incidence of cardiovascular disease such as arrhythmias and the use of antiarrhythmic drugs 
increases with age.
82
 
 
Chloroquine  
 Due to the high prevalence of chloroquine resistant P. falciparum malaria in most parts of 
the world, chloroquine use has significantly declined over the years. Chloroquine is indicated for 
malaria prophylaxis and treatment of susceptible plasmodium species.  Hydroxychloroquine is 
not commonly used for malaria prevention or treatment, but the adverse effect profile and drug-
drug interactions are similar to chloroquine. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/jtm
/advance-article-abstract/doi/10.1093/jtm
/taz089/5644627 by C
hapm
an U
niversity user on 06 D
ecem
ber 2019
26 
 
Pharmacologic/Pharmacokinetic Effects 
 Chloroquine is a 4-aminoquinoline and an anti-protozoal agent. While the exact 
mechanism of action of chloroquine is not well known, it is thought to kill plasmodium in the 
erythrocytes by the prevention of the polymerization of heme, leading to accumulation in the 
parasite, which is toxic. Chloroquine is readily absorbed from the GI tract, and it is extensively 
distributed in tissues such as liver, spleen, kidney, and lung.
22
 It is metabolized in the liver by 
CYP2C8 and CYP3A4 enzymes, and about 55% of the medication is renally eliminated.
19, 132, 133
  
There are currently no dosage adjustment recommendations for chloroquine. However, it 
has been recommended to administer 50% of the chloroquine dose if the patient’s CrCl is less 
than 10 mL/min.
134
 
 
Pharmacodynamic Effects 
Dermatologic 
Pruritis can occur with chloroquine use and has a higher frequency in dark-skinned 
individuals.
135
 Administration of an antihistamine at the same time as the administration of 
chloroquine may help decrease the incidence of pruritis in susceptible individuals.
136
 However, 
the American Geriatrics Society (AGS) 2019 Updated AGS Beers Criteria for Potentially 
Inappropriate Medication Use in Older Adults states that first-generation antihistamines should 
be avoided due to increased risk of adverse effects.
15
 Some examples of first-generation 
antihistamines are brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, 
hydroxyzine, and meclizine. 
Cardiac 
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Although rare, QRS complex and QT interval prolongation along with cardiotoxicity 
have been observed with chloroquine use.
137
 Older adults may be at a greater risk for 
cardiotoxicity as the incidence of cardiovascular disease such as arrhythmias and the use of 
antiarrhythmic drugs increases with age.
82
 
Other 
 Rarely, chloroquine may cause GI disturbances such as nausea, vomiting, and diarrhea, 
hypoglycemia, hepatitis, elevated liver enzymes, and headache.
138
 Taking chloroquine with food 
may help alleviate any GI adverse effects. Other adverse effects that may occur very seldom are 
central nervous system changes, myopathy, photosensitivity, hearing loss, and blood disorders.
138
 
If used chronically for long term prophylaxis, keratopathy and retinopathy may occur. For 
indications other than acute malaria, the use of chloroquine is contraindicated in the presence of 
retinal or visual field changes.
139
   
 
Drug-drug Interactions  
Chloroquine should be used cautiously with cimetidine, ampicillin, praziquantel, 
thyroxine, cyclosporine, methotrexate, and antiepileptic medications due to drug interactions 
using different mechanisms.
140-146
 (Table 1) It has been postulated that cimetidine may inhibit the 
elimination of chloroquine and that chloroquine may decrease gastric emptying and gut motility 
resulting in decreased ampicillin bioavailability.
140, 141
 The interaction between chloroquine and 
praziquantel is not well understood, but it has been proposed that chloroquine may increase the 
catabolism of thyroid hormones via enzymatic induction.
143, 144
 Chloroquine may increase 
cyclosporine levels by inhibiting its metabolism through direct enzyme inhibition or by enzyme 
competition.
142, 147
  Chloroquine may reduce the bioavailability of methotrexate when co-
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administered.
146
  Carbamazepine was reported to antagonize the effect of chloroquine.
138
 
Chloroquine may also increase the risk for acute dystonic reactions when taken with 
metronidazole, and it should be taken at least 4 hours apart from antacids as antacids may 
decrease the absorption of chloroquine.
148, 149
 (Table 1) Some medications (ie. antipsychotic 
medications, cisapride, dronedarone, etc) are contraindicated with chloroquine due to the 
increased risk for QT prolongation.
138
 (Table 1) Antidepressant medications such as citalopram, 
escitalopram, fluoxetine, and some tricyclic antidepressants also pose a great risk for QT 
prolongation with chloroquine.
36
 (Table 1)   
 
Drug-disease interactions and Considerations in Older Adults 
G6PD deficiency 
Chloroquine may also cause hemolysis in glucose-6 phosphate dehydrogenase (G6PD) 
deficient individuals and especially if these patients are taking medications which can also cause 
hemolysis. These medications include dapsone, methylene blue, nitrofurantoin, phenazopyridine, 
primaquine, rasburicase, and tolonium chloride.
150
 While it is not recommended to perform 
G6PD testing, if the individual has the enzyme deficiency, it should not be used.  Periodic checks 
of complete blood cell counts are important if patients are taking chloroquine for an extended 
period of time.  
Cardiac 
A scientific statement by the American Heart Association in 2016 concluded that 
chloroquine might cause myocardial toxicity or exacerbate underlying myocardial dysfunction in 
cases of long-term use and with high doses.
137
 Older adults, female sex, long duration of therapy 
(3 months – 27 years; mean > 10 years), high doses, preexisting cardiac disease, and renal 
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insufficiency are all risk factors for cardiotoxicity.
137, 151, 152
 Drug-drug interaction should always 
be checked with chloroquine especially in older adults to ensure that the risk for QT prolongation 
and cardiotoxicity is minimized.  
Hypoglycemia 
Hypoglycemia has been reported with chloroquine. As older adults are at a higher risk for 
hypoglycemia during treatment for diabetes with glucose lowering medications, close monitoring 
of blood sugars is warranted if chloroquine is used for malaria prevention or treatment.
18
  
Ophthalmic 
The risk of retinopathy is also increased if a patient has decreased renal function or is 
taking tamoxifen.
153, 154
 Older adults should have normal renal function when taking chloroquine 
as these individuals are more prone to renal impairment.
12
 Age, however, does not seem to 
correlate to retinal toxicity.
154
 The American Academy of Ophthalmology (AAO) recommends 
baseline screening for retinal toxicity and annual screening for patients taking chloroquine for 
longer than 5 years as the risk of retinal toxicity increases from less than 1% over 5 years to 2% 
up to 10 years, and to 20% after 20 years.
153
 
Other 
Chloroquine may exacerbate psoriasis, neurological, retinal, or gastrointestinal 
disorders.
138
 Exacerbation and, rarely, induction of plaque-type psoriasis can occur, typically 
after 4 to 12 weeks of use, but the actual risk is unknown.
155
  Chloroquine should be used with 
caution in patients with hepatic impairment as it may accumulate in the liver, thereby resulting in 
hepatic toxicity. This is an important consideration in older adults as they are more likely to have 
multiple co-morbid conditions, including decreased hepatic function.
12, 66
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As older adults may have more comorbid conditions such as diabetes mellitus, heart 
disease, and retinopathy, the risk for hypoglycemia, cardiotoxicity, QT interval prolongation, and 
retinopathy with chloroquine should be considered prior to prescribing chloroquine for these 
individuals.
108, 156
 This is especially true if an older adult requires long term malaria prophylaxis.  
 
Limitations 
Limited data was found on drug-drug interactions in older patients once the literature 
search was performed. The limited data and lack of recent literature prevented the authors from 
performing a systematic review or meta-analysis due to the lack of heterogeneity in the evidence.  
 
Conclusion 
While the proportion of older adults traveling to malarious areas is small compared to 
younger groups, special attention is warranted due to their unique changes in physiology and 
how drugs are affected by their pharmacokinetic parameters.  In addition, older adults are more 
likely to take multiple medications and have chronic medical conditions. As a result, older adults 
may be at a higher risk for drug-drug and drug-disease interactions such as cardiotoxicity or over 
anticoagulation.  With some exceptions, older adults are not more likely to experience adverse 
effects or decreased efficacy due to drug-drug interactions any differently than younger groups. 
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Table 1. Summary of Antimalarial Drug-Drug Interactions 
 
Generic 
Drug Name 
 
High Risk Interacting 
Drugs 
Quality of 
Documentation/Reco
mmended action
ⱡ 
Drug-Drug Considerations 
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Mefloquine  QT prolongation 
drugs 
  
Quality of 
documentation varies 
based on 
drug/Contraindicated 
or use with extreme 
caution 
 Caution with drugs that 
affect cardiac conduction 
(B-blocker, digoxin, 
amiodarone, etc.) due to 
QT prolongation 
 
 Rifampin Good/Avoid 
concurrent use 
 Decreased exposure with 
concurrent rifampin 
 Ketoconazole Good/Contraindicate
d 
 Increased exposure with 
concurrent ketoconazole 
and increased risk for 
cardiotoxicity 
Chloroquine  Cyclosporine (↑) 
 
Good/Avoid 
concurrent use 
 Monitor cyclosporine 
levels for toxicity 
 
 Tamoxifen Fair/Avoid 
concurrent use 
 Increased risk for 
retinopathy 
 QT prolongation 
drugs  
Quality of 
documentation varies 
based on 
drug/Contraindicated 
or use with extreme 
caution 
 Augmentation of QT 
prolongation effect (ie. 
some antidepressants, 
antiarrhythmics, certain 
antipsychotics, some 
HIV medications, certain 
antiemetics, etc.)  
 Cimetidine (↑) 
 
Good/Avoid 
concurrent use 
 Suggest switching to 
another anti-ulcer 
medication with less 
potential to alter the 
pharmacokinetics of 
chloroquine 
 Carbamazepine 
(↓) 
Fair/Avoid 
concurrent use 
 
 Praziquantel (↓) 
 Thyroxine (↓) 
 
Good/Precaution  Decreased bioavailability 
of these agents 
 Consider dose increase of 
praziquantel is patient is 
not responding to 
treatment 
 Monitor TSH levels 
when starting and 
discontinuing 
chloroquine therapy  
 Antacids Good/Avoid 
concurrent use 
 Reduced absorption with 
antacids 
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 Administration should be 
separated by at least four 
hours 
Doxycycline  Antacids 
 Bismuth 
subsalicylate 
 Oral iron 
Good/Avoid 
concurrent use 
 Doxycycline should be 
taken at least one to two 
hours before aluminum, 
calcium or magnesium 
containing products 
 Doxycycline should be 
taken at least two to three 
hours before the bismuth 
subsalicylate dose 
 Iron salts should be given 
not less than three hours 
before or two hours after 
the doxycycline dose 
 Rifampin Good/Avoid 
concurrent use 
 May decrease plasma 
concentration of 
doxycycline 
 Carbamazepine 
 Phenytoin  
 Phenobarbital 
Fair/Avoid 
concurrent use 
 May decrease plasma 
concentration of 
doxycycline 
 Warfarin (↑) Fair/Precaution  Closely monitor INR at 
initiation and withdrawal 
of doxycycline therapy  
and reassess periodically 
during concurrent 
therapy 
 Methotrexate (↑) Good/Use with 
caution 
 Closely monitor for 
evidence of methotrexate 
toxicity especially at high 
methotrexate doses; 
consider an alternative to 
doxycycline 
Primaquine  Quinacrine Contraindicated (PI)  Manufacturer 
recommendation (may 
increase toxicity of 
primaquine) 
Atovaquone-
proguanil 
 Ritonavir, 
efavirenz, 
rifamycins 
Good/Use not 
recommended 
 Decreased plasma 
concentration of 
atovaquone/proguanil 
 Tetracycline Good/Use not 
recommended 
 Decreased plasma 
concentration of 
atovaquone/proguanil 
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 Metoclopramide Fair/Use with caution 
only if other options 
not available 
 Decreased bioavailability 
of atovaquone/proguanil 
 Warfarin (↑) Good/Precaution  Closely monitor INR at 
initiation and withdrawal 
of antimalarial therapy 
Tafenoquine  Cisplatin 
 Metformin  
 Oxaliplatin 
Fair/ 
Precaution 
 Increases levels of 
multidrug and toxin 
extrusion (MATE1) 
substrates and organic 
cation transporter 2 
(OCT2) substrates 
Artemisinins 
(Artesunate, 
Artemether/L
umefantrine) 
 Rifampin () 
 Ketoconazole 
() 
 QT prolongation 
drugs  
Excellent/Contraindic
ated 
 
 Avoid with potent CYP 
3A4 inducers or 
inhibitors  
 Augmentation of QT 
prolongation effect  
 Darunavir, 
ritonavir, 
lopinavir, 
ritonavir, 
nevirapine, 
efavirenz, 
etravirine 
Fair/Precaution  Caution with potent CYP 
3A4 inducers or 
inhibitors 
±
 Classification and strength of evidence adapted from Micromedex Online Solutions. 
Greenwood Village, CO: Truven Health Analytics. http://micromedex.com/. Accessed date 
August 2019 
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